All Stories

  1. Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial
  2. Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study
  3. Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer
  4. Optimising mastectomy with a focus on skin and nipple-sparing approaches: a multidisciplinary point of view
  5. Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study
  6. Corrigendum to “Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study” [The Breast, Volume 83 (2025) 104537]
  7. What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy?
  8. Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)
  9. BJS commission on the surgical management of the axilla in breast cancer
  10. Local management of second breast cancer event after primary breast conserving therapy: The patient’s perspective
  11. Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study
  12. Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial
  13. Impact of axillary staging after neoadjuvant chemotherapy for breast cancer on arm morbidity: one-year results from the AXSANA cohort study
  14. Impact of prior radiotherapy and implant-based reconstruction on microvascular outcome in DIEP flap breast reconstruction
  15. Long-term oncological outcomes after nipple-sparing mastectomy and implant-based immediate breast reconstruction in a large population-based cohort
  16. Survival after breast conservation versus mastectomy in ductal carcinoma in situ of the breast: a population-based Swedish register study
  17. Abstract P2-10-25: AXSANA: Status of the international prospective multicenter cohort study evaluating different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)
  18. Abstract RF2-03: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655)
  19. Abstract P3-12-16: MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4 / iBRA-NET, NCT 05559411)
  20. Abstract P3-10-29: Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387) - On the way to identify women at risk of developing seroma after mastectomy
  21. Abstract PS6-06: Upstage of N-Stage by Diagnostic Axillary Lymph Node Dissection in Patients w/ Isolated Tumor Cells or Micrometastases in Sentinel/Target Lymph Node after Neoadjuvant Chemotherapy - Results from the Prospective Multicenter AXSANA / EUB...
  22. Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study (NCT04373655).
  23. Setting a precedent: Development of a core outcome set for locoregional treatment outcome reporting in neoadjuvant breast cancer trials.
  24. Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy: results from the prospective SENOMIC trial
  25. Treatment strategies for triple-negative primary breast cancer in older women: a systematic review
  26. Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer—a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
  27. P286: Radar localization for targeted axillary dissection in breast cancer patients undergoing primary systemic treatment: a sub-analysis of the AXSANA study
  28. P464: Treatment Strategies for Triple-Negative Primary Breast Cancer in Older Women: A Systematic Review
  29. Radiation therapy volumes after primary systemic therapy in breast cancer patients: an international EUBREAST survey
  30. Prediction of High Nodal Burden in Patients With Sentinel Node–Positive Luminal ERBB2-Negative Breast Cancer
  31. Axillary clearance and chemotherapy rates in ER+HER2− breast cancer: secondary analysis of the SENOMAC trial
  32. ‘Balancing Challenges and Personal Resources’: A Qualitative Study of Women's Experiences of Arm Impairment After Axillary Surgery for Breast Cancer
  33. Idiopathic Granulomatous Mastitis as a Benign Condition Mimicking Inflammatory Breast Cancer: Current Status, Knowledge Gaps and Rationale for the GRAMAREG Study (EUBREAST-15)
  34. Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review
  35. Surgical complications after immediate implant-based breast reconstruction for breast cancer in women over 65 years
  36. Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial
  37. Timing and type of breast reconstruction in SweBRO 3: long-term outcomes
  38. Quality assessment of radiotherapy in the prospective randomized SENOMAC trial
  39. 71486 - Surgical complications after immediate implant-based breast reconstruction for breast cancer in women ≥ 65 years of age
  40. 71487 - The role of previous implant-based breast reconstruction and radiotherapy for surgical complications in DIEP breast reconstruction
  41. Abstract PO4-19-04: AXSANA – EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy
  42. Abstract PO5-19-02: I-PREPARE: International Prospective REgistry on Pre-pectorAl breast Reconstruction (EUBREAST 11R-NCT 05817175)
  43. Abstract PO4-18-12: MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET, NCT 05559411)
  44. Abstract PO1-23-02: Magnetic seeds used for the detection of target lymph nodes after neoadjuvant therapy for early breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
  45. Abstract PO1-19-06: Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: the randomized Neo-ACT trial
  46. Abstract PO3-23-03: Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
  47. Abstract GS02-06: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial
  48. Abstract PO1-19-03: The T-REX trial: a randomized international non-inferiority trial on Tailored Regional EXternal beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases
  49. Which real indications remain for mastectomy?
  50. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
  51. Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project
  52. Targeted axillary dissection: worldwide variations in clinical practice
  53. National long-term patient-reported outcomes following mastectomy with or without breast reconstruction: The Swedish Breast Reconstruction Outcome Study Part 2 (SweBRO 2)
  54. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
  55. Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study
  56. Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial
  57. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus
  58. Uncertainties and controversies in axillary management of patients with breast cancer
  59. MELODY (Methods for Localization of Different Types of Breast Lesions): A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).
  60. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy
  61. Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411)
  62. Axillary staging in node-positive breast cancer converting to node negativity through neoadjuvant chemotherapy: Current evidence and perspectives
  63. Locoregional Therapy: From Mastectomy to Reconstruction, Targeted Surgery, and Ultra-Hypofractionated Radiotherapy
  64. Capsular inflammation after immediate breast reconstruction – Gene expression patterns and inflammatory cell infiltration in irradiated and non-irradiated breasts
  65. Medical and surgical postoperative complications after breast conservation versus mastectomy in older women with breast cancer: Swedish population-based register study of 34 139 women
  66. Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
  67. Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey
  68. Effectiveness of Single vs Multiple Doses of Prophylactic Intravenous Antibiotics in Implant-Based Breast Reconstruction
  69. Long-term outcomes of implant-based immediate breast reconstruction with and without radiotherapy: a population-based study
  70. Major surgical postoperative complications and survival in breast cancer: Swedish population-based register study in 57 152 women
  71. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey
  72. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy
  73. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial
  74. AXSANA – AXillary Surgery After NeoAdjuvant Treatment: Eine prospektive, multizentrische Kohortenstudie der EUBREAST-Studiengruppe zur Bewertung verschiedener chirurgischer Verfahren des axillären Stagings bei initial nodal-positiven PatientInnen nach ...
  75. 120P AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoa...
  76. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy
  77. Abstract OT1-04-04: AXSANA - EUBREAST 3 (axillary surgery after neoadjuvant treatment): An international prospective multicenter cohort study of the EUBREAST study group to evaluate different surgical methods of axillary staging (sentinel lymph node bi...
  78. Abstract P1-01-16: Perspectives on axillary management after primary systemic treatment: An international EUBREAST survey
  79. Eradication of Potential In-Transit Metastasis in Breast-Conserving Surgery—Reply
  80. Effect of radiotherapy on expanders and permanent implants in immediate breast reconstruction: long-term surgical and patient-reported outcomes in a large multicentre cohort
  81. ASO Visual Abstract: Retrospective Multicenter Analysis Comparing Conventional with Oncoplastic Breast-Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study
  82. Retrospective, Multicenter Analysis Comparing Conventional with Oncoplastic Breast Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study
  83. Survival in breast cancer patients with a delayed DIEP flap breast reconstruction after adjustment for socioeconomic status and comorbidity
  84. Targeted Removal of Axillary Lymph Nodes After Carbon Marking in Patients with Breast Cancer Treated with Primary Chemotherapy
  85. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing ...
  86. Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status
  87. Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease
  88. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial
  89. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status
  90. Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study
  91. Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial
  92. Recurrence and survival after standard versus oncoplastic breast-conserving surgery for breast cancer
  93. Breast reconstruction patterns from a Swedish nation-wide survey
  94. AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinica...
  95. Target Lymph Node Biopsy (TLNB) nach Kohlenstoffmarkierung bei Mammakarzinom-Patientinnen im Rahmen der primären Systemtherapie – Ergebnisse der TATTOO-Studie
  96. Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction
  97. Knowledge gaps in oncoplastic breast surgery
  98. AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinica...
  99. TLNB (Target-Lymph-Node-Biopsy) nach Kohlenstoffmarkierung bei Mammakarzinom-Patientinnen nach primärer Systemtherapie Ergebnisse der TATTOO-Studie
  100. Abstract OT3-01-01: Feasibility of carbon tattooing for targeted lymph node biopsy in breast cancer patients treated by primary systemic therapy (TATTOO trial)
  101. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
  102. Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019
  103. Influence of socioeconomic status on immediate breast reconstruction rate, patient information and involvement in surgical decision-making
  104. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
  105. Immediate Breast Reconstruction
  106. Superior Survival After Breast Conservation Versus Mastectomy Despite Adjustment for Comorbidity and Socioeconomic Status: Median Follow-Up of Six Years on 48986 Breast Cancer Patients From Swedish National Registers
  107. Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information
  108. Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer
  109. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant
  110. A gap analysis of opportunities and priorities for breast surgical research
  111. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy
  112. Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation
  113. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes
  114. Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction
  115. Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting
  116. What Is the Best Management of cN0pN1(sn) Breast Cancer Patients
  117. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial
  118. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer
  119. Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer
  120. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study
  121. Impact of previous surgery on sentinel lymph node mapping: Hybrid SPECT/CT before and after a unilateral diagnostic breast excision
  122. National study of the impact of patient information and involvement in decision-making on immediate breast reconstruction rates
  123. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer
  124. The oncological safety of nipple-sparing mastectomy – A Swedish matched cohort study
  125. Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis
  126. Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinomain situ
  127. Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort
  128. Authors' reply: Causes of false-negative sentinel node biopsy in patients with breast cancer (Br J Surg2013; 100: 775-783)
  129. High Prevalence of Human Cytomegalovirus Proteins and Nucleic Acids in Primary Breast Cancer and Metastatic Sentinel Lymph Nodes
  130. Causes of false-negative sentinel node biopsy in patients with breast cancer
  131. Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes
  132. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients
  133. Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients
  134. Prediction of Non-Sentinel Lymph Node Status in Breast Cancer Patients with Sentinel Lymph Node Metastases: Evaluation of the Tenon Score
  135. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer
  136. Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function
  137. Breast Cancer Survival in Relation to the Metastatic Tumor Burden in Axillary Lymph Nodes
  138. Axillary Recurrence Rate After Negative Sentinel Node Biopsy in Breast Cancer
  139. Sentinel node biopsy for breast cancer larger than 3 cm in diameter